BioNTech SE (NASDAQ:BNTX) is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an independent monitoring committee concluded that continuing the trial was unlikely to demonstrate effectiveness.
The decision is more concerning than a routine trial disappointment because the committee identified a numerical imbalance in overall survival between the study groups. The magnitude and cause of that imbalance have not been disclosed, but the development raises questions about BioNTech’s work in colorectal cancer and the broader challenge of using mRNA vaccines against tumors historically resistant to immunotherapy.
Bull Case
Ending the study allows BioNTech and partner Genentech to stop investing in a trial that an independent committee considered unlikely to produce a positive result. The committee was responsible for monitoring the study’s safety and integrity, giving its recommendation greater weight than an internal commercial decision. The trial was testing a particularly difficult treatment setting. Patients had high-risk, mid-stage colorectal cancer, had undergone surgery and chemotherapy, and still had traces of cancer DNA in their blood. Autogene cevumeran was administered alone and compared with standard watchful waiting to determine whether it could prevent the disease from returning.
Although this study will end, BioNTech said the decision will not affect its separate autogene cevumeran trial in pancreatic cancer. That trial uses the vaccine in combination with Roche’s Tecentriq, rather than as a standalone treatment, with data expected in 2031. BioNTech also has other opportunities to evaluate whether its mRNA technology can work in different tumor types. The company is developing BNT113 for head and neck cancer, with interim trial data expected later this year. Results from that program could provide a nearer-term indication of whether the colorectal setback reflects one trial or a broader platform challenge.
The company is not dependent solely on mRNA cancer vaccines either. Reuters reported that the setback will probably accelerate BioNTech’s shift toward antibody-drug conjugates and bispecific cancer therapies, including the experimental drug pumitamig. A diversified oncology pipeline gives BioNTech other development paths if some personalized vaccines fail.
Bear Case
The overall-survival imbalance is the most serious concern. Analysts said the wording probably indicates that more deaths occurred in the vaccine group than in the control group, although neither BioNTech nor the monitoring committee disclosed the underlying numbers. BMO Capital Markets analyst Evan Seigerman described the update as more concerning than a conventional futility stop because of that imbalance. Without details about its size or cause, investors cannot determine whether the result reflects the treatment, differences between the patient groups, or another factor.
The failure may also have implications beyond colorectal cancer. Analysts noted that colorectal and pancreatic cancers are considered “cold” tumors that have historically responded poorly to immunotherapy. They said the result could weaken expectations for BioNTech’s pancreatic study, even though that trial combines the vaccine with Tecentriq. The long timeline creates additional uncertainty. Pancreatic-cancer data are not expected until 2031, leaving investors without a near-term answer about autogene cevumeran’s potential in another cold tumor.
The contrast with recent melanoma results is also notable. Days earlier, Merck and Moderna reported that their personalized mRNA vaccine reduced recurrence and spread in a study of more than 1,000 high-risk melanoma patients. That success had lifted BioNTech shares 20%, but the company’s US-listed shares fell 7.5% after its colorectal announcement, according to Reuters.
Conclusion
Stopping the colorectal study is a material setback for autogene cevumeran, particularly because the independent committee identified an unexplained overall-survival imbalance. It also increases uncertainty around BioNTech’s remaining work in tumors considered difficult to treat with immunotherapy.
BioNTech still has other mRNA programs and a growing non-mRNA oncology pipeline. The next important readout will come from BNT113 later this year, while the longer-term question is whether autogene cevumeran can perform differently in pancreatic cancer when combined with another therapy.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
